Spots Global Cancer Trial Database for A Study of M701 (EpCAM and CD3) in Malignant Ascites
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of M701 (EpCAM and CD3) in Malignant Ascites
Official Title: A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability and PK/PD of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody Via Intraperitoneal Infusion in Malignant Ascites
Study ID: NCT04501744
Study Description
Brief Summary: This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
Detailed Description: To evaluate the safety and tolerability of multiple ascending doses of M701 administered intraperitoneally in patients with malignant ascites.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact Details
Name: Jianming Xu
Affiliation: 307 Hospital of PLA
Role: PRINCIPAL_INVESTIGATOR
Name: Shixuan Wang
Affiliation: Tongji Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
